Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

2.

Advanced breast cancer patients living longer thanks to improvements in treatment and care

3.

Beyond What Is Visible in Myelofibrosis?

4.

Early-Onset Colorectal Cancer in Male Veterans is Predicted by Risk Factors.

5.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot